Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Multicenter, Randomized, Open-label, Two-Arm Study to Evaluate the Clinical Efficacy and Safety of OHB-607 Compared to Standard Neonatal Care for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease of Prematurity

NCT03253263 is registered in ClinicalTrials.gov with OHB Neonatology Ltd. as lead sponsor.

NCT NCT03253263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03253263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Multicenter, Randomized, Open-label, Two-Arm Study to Evaluate the Clinical Efficacy and Safety of OHB-607 Compared to Standard Neonatal Care for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease of Prematurity
Lead sponsor
OHB Neonatology Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 9, 2019
Completion date
January 21, 2028
Enrollment
295 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

bronchopulmonary dysplasia, chronic lung disease of prematurity, intraventricular hemorrhage, retinopathy of prematurity (rop)